Novartis Slapped With New $49m Fine For Korea ‘Rebates’
Executive Summary
Novartis's South Korean subsidiary has been hit with a new fine of around $49m and reimbursement suspensions for a number of its drugs under a new ministerial action related to illegal "rebate" payments made to prescribers.